Novel Synthesis and Biological Evaluation of Enigmols as Therapeutic Agents for Treating Prostate Cancer
作者:Ethel C. Garnier-Amblard、Suzanne G. Mays、Richard F. Arrendale、Mark T. Baillie、Anatoliy S. Bushnev、Deborah G. Culver、Taylor J. Evers、Jason J. Holt、Randy B. Howard、Lanny S. Liebeskind、David S. Menaldino、Michael G. Natchus、John A. Petros、Harsha Ramaraju、G. Prabhakar Reddy、Dennis C. Liotta
DOI:10.1021/ml2000164
日期:2011.6.9
Enigmol is a synthetic, orally active 1-deoxysphingoid base analogue that has demonstrated promising activity against prostate cancer. In these studies, the pharmacologic roles of stereochemistry and N-methylation in the structure of enigmols were examined. A novel enantioselective synthesis of all four possible 2S-diastereoisomers of enigmol (2-aminooctadecane-3,5-diols) from l-alanine is reported
Enigmol是一种合成的,口服活性的1-deoxysphingoid基础类似物,已显示出对前列腺癌有希望的活性。在这些研究中,研究了立体化学和N-甲基化在烯乙酚结构中的药理作用。据报道从l-丙氨酸中合成了烯醇(2-氨基十八烷-3,5-二醇)的所有四种可能的2S-非对映异构体的新型对映选择性合成,其特征在于l-丙氨酸硫醇酯与(E)之间的Liebeskind-Srogl交叉偶联反应)-戊基-1-烯基硼酸为关键步骤。四种Enigmol非对映异构体和2S,3S,5S-N-甲基Enigmol对两种前列腺癌细胞系(PC-3和LNCaP)的体外生物学评估表明,除一种非对映异构体外,所有化合物均显示出强大的溶瘤活性。在人类前列腺癌的裸鼠异种移植模型中,Enigmol与标准前列腺癌疗法(雄激素剥夺或多西他赛)同样有效,两种Enigmol非对映异构体2S,3S,5R-enigmol和2S,3R,5S-eni